Literature DB >> 21792061

HIV infection and progression of carotid and coronary atherosclerosis: the CARE study.

Alexandra Mangili1, Joseph F Polak, Sally C Skinner, Jul Gerrior, Heidi Sheehan, Anita Harrington, Christine A Wanke.   

Abstract

BACKGROUND: Progression of carotid intima-media thickness (c-IMT) and coronary artery calcium (CAC) are increasingly used as surrogates for vascular risk. We assessed the predictors of c-IMT and CAC progression in a large longitudinal cohort of HIV-infected adults.
METHODS: c-IMT, CAC scores, and vascular and HIV risk factors were evaluated at baseline and at 3-year follow-up in 255 HIV-infected adults. Multivariate regression was used to determine the predictors of atherosclerotic progression.
RESULTS: The mean change in c-IMT per year of follow-up was 0.016 mm for the common and 0.020 mm for the internal. Significant predictors of yearly progression were age, systolic blood pressure, triglycerides, and insulin for common c-IMT and triglycerides >=150 mg/dL, glucose >126 mg/dL, use of glucose-lowering medications, quantitative insulin sensitivity check index, high waist circumference, and current smoking for internal c-IMT. Twenty-eight percent had CAC progression. Of those with zero CAC at baseline, 32% had detectable scores at follow-up. Of those with detectable CAC at baseline, 26% had progression at follow-up. For CAC score, quantitative insulin sensitivity check index, apolipoprotein B, and triglycerides predicted progression. Those with abnormal surrogate markers at baseline were more likely to have the metabolic syndrome reversed and be started on antihypertensive medications over the 3-year follow-up period than those who had no abnormalities at baseline.
CONCLUSIONS: Although c-IMT and CAC progression rates in HIV-infected patients appear higher than expected for this age and risk groups, traditional cardiovascular risk factors remain the strongest determinants of carotid and coronary atherosclerotic disease progression in HIV-infected patients. Aggressive cardiovascular risk reduction is effective at slowing the atherosclerotic progression in those with preexisting disease.

Entities:  

Mesh:

Year:  2011        PMID: 21792061     DOI: 10.1097/QAI.0b013e31822d4993

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  27 in total

1.  Associations of cocaine use and HIV infection with the intestinal microbiota, microbial translocation, and inflammation.

Authors:  Gretchen E Volpe; Honorine Ward; Mkaya Mwamburi; Duy Dinh; Seema Bhalchandra; Christine Wanke; Anne V Kane
Journal:  J Stud Alcohol Drugs       Date:  2014-03       Impact factor: 2.582

2.  Short communication: effects of omega-3 fatty acids on triglycerides and high-density lipoprotein subprofiles in HIV-infected persons with hypertriglyceridemia.

Authors:  Anu Paranandi; Bela F Asztalos; Alexandra Mangili; Jefferey Kuvin; Jul Gerrior; Heidi Sheehan; Sally C Skinner; Alice M Tang; Christine A Wanke
Journal:  AIDS Res Hum Retroviruses       Date:  2014-08       Impact factor: 2.205

3.  HIV and coronary artery calcium score: comparison of the Hawaii Aging with HIV Cardiovascular Study and Multi-Ethnic Study of Atherosclerosis (MESA) cohorts.

Authors:  Dominic Chow; Rebekah Young; Nicole Valcour; Richard A Kronmal; Corey J Lum; Nisha I Parikh; Russell P Tracy; Matthew Budoff; Cecilia M Shikuma
Journal:  HIV Clin Trials       Date:  2015-06-03

4.  An Algorithm Approach to Determining Smoking Cessation Treatment for Persons Living With HIV/AIDS: Results of a Pilot Trial.

Authors:  Karen L Cropsey; Bianca F Jardin; Greer A Burkholder; C Brendan Clark; James L Raper; Michael S Saag
Journal:  J Acquir Immune Defic Syndr       Date:  2015-07-01       Impact factor: 3.731

5.  Effects of lifestyle modification and metformin on atherosclerotic indices among HIV-infected patients with the metabolic syndrome.

Authors:  Kathleen Fitch; Suhny Abbara; Hang Lee; Eleni Stavrou; Rachel Sacks; Theresa Michel; Linda Hemphill; Martin Torriani; Steven Grinspoon
Journal:  AIDS       Date:  2012-03-13       Impact factor: 4.177

6.  Altered lipid concentrations of liver, heart and plasma but not brain in HIV-1 transgenic rats.

Authors:  Ameer Y Taha; Mireille Basselin; Epolia Ramadan; Hiren R Modi; Stanley I Rapoport; Yewon Cheon
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2012-08-29       Impact factor: 4.006

Review 7.  Prevention of stroke in people living with HIV.

Authors:  Ivy Nguyen; Anthony S Kim; Felicia C Chow
Journal:  Prog Cardiovasc Dis       Date:  2020-01-31       Impact factor: 8.194

Review 8.  Tobacco use and cessation in HIV-infected individuals.

Authors:  Kristine K Browning; Mary Ellen Wewers; Amy K Ferketich; Philip Diaz
Journal:  Clin Chest Med       Date:  2013-04-08       Impact factor: 2.878

9.  Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection.

Authors:  Duy M Dinh; Gretchen E Volpe; Chad Duffalo; Seema Bhalchandra; Albert K Tai; Anne V Kane; Christine A Wanke; Honorine D Ward
Journal:  J Infect Dis       Date:  2014-07-23       Impact factor: 5.226

10.  The metabolic and cardiovascular consequences of obesity in persons with HIV on long-term antiretroviral therapy.

Authors:  John R Koethe; Heather Grome; Cathy A Jenkins; Spyros A Kalams; Timothy R Sterling
Journal:  AIDS       Date:  2016-01-02       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.